FDA Solicits Feedback on ANDA Submissions – Amendments to ANDAs Under GDUFA Guidance, Appendix A

August 12, 2022

Ahead of this year’s reauthorization of the Generic Drug User Fee Amendments (GDUFA) , FDA has established a docket to solicit comments on the content of Appendix A in the July 2018 guidance for industry entitled “ANDA Submissions--Amendments to Abbreviated New Drug Applications Under GDUFA” (ANDA Amendments Guidance). The agency is soliciting comments on the content of Appendix A to fulfill its commitment described in section IX.B. of the GDUFA Reauthorization Performance Goals and Program Enhancements Fiscal Years 2023-2027 Commitment Letter (GDUFA III Commitment Letter).

In the GDUFA III Commitment Letter, FDA agreed to issue a Federal Register notice to solicit public comment on the content of Appendix A in the ANDA Amendments Guidance on or before April 30, 2023. The ANDA Amendments Guidance describes amendment classifications (“major” or “minor” amendments) and categories (amendments subject to “priority” or “standard” review goals) and explains how amendment submission classification and category may affect an amendment’s performance goal date. Appendix A in the ANDA Amendments Guidance is a non-exhaustive list of examples of deficiencies that FDA may consider major.

With this notice, FDA is seeking comments on the examples of major deficiencies listed in Appendix A of the ANDA Amendments Guidance, as well as comments on how any proposed revisions to that list could be beneficial to industry in understanding ANDA amendment classification. For more details, please see the Federal Register notice.

Interested in learning more? Contact us today to find out how we can help with your global regulatory needs.

TAGS:

July 14, 2020

Improving Cost Efficiency, Speed, and Completeness of Generic Applications

An abbreviated new drug application (ANDA) is a “streamlined” marketing application that is submitted to the FDA for review containing information and data about a generic drug product. Once...

November 11, 2014

FDA Prepares for GDUFA Commitments with Controlled Correspondence Guidance

With the implementation of GDUFA, FDA defined the rules and specific protocol for submitting controlled correspondence to the Office of Generic Drugs (OGD) in a draft guidance published on August 27,...

April 13, 2016

FDA Works to Reduce Medical Errors, Part One: Background & Overview of FDA’s Proprietary Naming Guidance

In September 2007, the Prescription Drug User Fee Act (PDUFA IV) was reauthorized and expanded, broadening and strengthening FDA’s drug safety program. As part of PDUFA’s reauthorization, the Agency...